• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial.

作者信息

Vermeire Séverine, Hébuterne Xavier, Tilg Herbert, De Hertogh Gert, Gineste Paul, Steens Jean-Marc

机构信息

Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.

Department of Gastroenterology and Clinical Nutrition, CHU of Nice, University Côte d'Azur, Nice, France.

出版信息

Gastroenterology. 2021 Jun;160(7):2595-2598.e3. doi: 10.1053/j.gastro.2021.02.054. Epub 2021 Mar 2.

DOI:10.1053/j.gastro.2021.02.054
PMID:33662385
Abstract
摘要

相似文献

1
Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial.ABX464用于中重度溃疡性结肠炎的诱导治疗及长期随访：IIa期试验结果
Gastroenterology. 2021 Jun;160(7):2595-2598.e3. doi: 10.1053/j.gastro.2021.02.054. Epub 2021 Mar 2.
2
Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.每日两次使用2毫克布地奈德泡沫剂可使远端溃疡性结肠炎患者的黏膜完全愈合。
J Crohns Colitis. 2016 Jul;10(7):828-36. doi: 10.1093/ecco-jcc/jjv208. Epub 2015 Nov 16.
3
Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis: Results from a Randomized Multicenter Study.三肽K(D)PT在轻至中度溃疡性结肠炎中耐受性良好：一项随机多中心研究的结果
Inflamm Bowel Dis. 2017 Feb;23(2):261-271. doi: 10.1097/MIB.0000000000001000.
4
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.每日一次布地奈德 MMX 治疗活动期轻中度溃疡性结肠炎：来自随机 CORE II 研究的结果。
Gut. 2014 Mar;63(3):433-41. doi: 10.1136/gutjnl-2012-304258. Epub 2013 Feb 22.
5
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.阿达木单抗治疗中重度溃疡性结肠炎儿科患者的疗效和安全性（ENVISION I）：一项随机、对照、3 期研究。
Lancet Gastroenterol Hepatol. 2021 Aug;6(8):616-627. doi: 10.1016/S2468-1253(21)00142-4. Epub 2021 Jun 19.
6
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.阿达木单抗可诱导并维持中重度溃疡性结肠炎患者的临床缓解。
Gastroenterology. 2012 Feb;142(2):257-65.e1-3. doi: 10.1053/j.gastro.2011.10.032. Epub 2011 Nov 4.
7
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.皮下注射戈利木单抗可维持中重度溃疡性结肠炎患者的临床应答。
Gastroenterology. 2014 Jan;146(1):96-109.e1. doi: 10.1053/j.gastro.2013.06.010. Epub 2013 Jun 14.
8
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.考比妥利莫德治疗中重度左侧溃疡性结肠炎（CONDUCT）：一项 2b 期随机、双盲、安慰剂对照、剂量范围诱导试验。
Lancet Gastroenterol Hepatol. 2020 Dec;5(12):1063-1075. doi: 10.1016/S2468-1253(20)30301-0. Epub 2020 Oct 5.
9
The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages.抗 HIV 候选药物 Abx464 通过激活巨噬细胞中 IL-22 的产生来抑制肠道炎症。
Sci Rep. 2017 Jul 7;7(1):4860. doi: 10.1038/s41598-017-04071-3.
10
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.抗 IP-10 抗体（BMS-936557）治疗溃疡性结肠炎：一项 II 期随机研究。
Gut. 2014 Mar;63(3):442-50. doi: 10.1136/gutjnl-2012-303424. Epub 2013 Mar 5.

引用本文的文献

1
Drug Development in Inflammatory Bowel Diseases: What Is Next?炎症性肠病的药物研发：下一步是什么？
Pharmaceuticals (Basel). 2025 Jan 30;18(2):190. doi: 10.3390/ph18020190.
2
MicroRNA signatures in the pathogenesis and therapy of inflammatory bowel disease.微小 RNA 特征在炎症性肠病发病机制和治疗中的作用。
Clin Exp Med. 2024 Sep 11;24(1):217. doi: 10.1007/s10238-024-01476-z.
3
Reduced Expression of miR-146a Potentiates Intestinal Inflammation following Alcohol and Burn Injury.miR-146a 表达降低可增强酒精和烧伤损伤后的肠道炎症。
J Immunol. 2024 Mar 1;212(5):881-893. doi: 10.4049/jimmunol.2300405.
4
Multiomics analysis identifies novel facilitators of human dopaminergic neuron differentiation.多组学分析鉴定出人类多巴胺能神经元分化的新型促进因子。
EMBO Rep. 2024 Jan;25(1):254-285. doi: 10.1038/s44319-023-00024-2. Epub 2023 Dec 19.
5
Epigenetic regulation and therapeutic strategies in ulcerative colitis.溃疡性结肠炎的表观遗传调控与治疗策略
Front Genet. 2023 Dec 15;14:1302886. doi: 10.3389/fgene.2023.1302886. eCollection 2023.
6
A Narrative Review of Cytokine Networks: Pathophysiological and Therapeutic Implications for Inflammatory Bowel Disease Pathogenesis.细胞因子网络的叙述性综述：对炎症性肠病发病机制的病理生理学和治疗意义
Biomedicines. 2023 Dec 6;11(12):3229. doi: 10.3390/biomedicines11123229.
7
ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial.ABX464（奥贝法齐莫德）用于有重症风险的COVID-19患者：miR-AGE，一项随机、双盲、安慰剂对照试验。
J Allergy Clin Immunol Glob. 2023 Jul 4;2(4):100140. doi: 10.1016/j.jacig.2023.100140. eCollection 2023 Nov.
8
Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies.炎症性肠病：新兴疗法与未来治疗策略
Biomedicines. 2023 Aug 11;11(8):2249. doi: 10.3390/biomedicines11082249.
9
Emerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials.溃疡性结肠炎的新兴疗法：近期临床试验的最新进展
Clin Exp Gastroenterol. 2023 Aug 17;16:147-167. doi: 10.2147/CEG.S375969. eCollection 2023.
10
Novel Small Molecules in IBD: Current State and Future Perspectives.新型小分子在炎症性肠病中的应用：现状与未来展望。
Cells. 2023 Jun 27;12(13):1730. doi: 10.3390/cells12131730.